|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
RESULTS Immunohistochemistry showed that USP9X was significantly overexpressed in 93 of 102 (91.1%) breast cancer tissue samples compared with 41 normal breast tissue samples and was associated with tumor size ≥5.0 cm (P<0.05).
|
31169265 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
USP9X is highly expressed in a number of tissue types and acts as both an oncogene and tumor suppressor in several human cancers.
|
30767316 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The deubiquitinase USP9X is involved in multiple diseases including neurodegeneration, epilepsy, and various types of tumors by targeting different substrates.
|
31059266 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Furthermore, in vivo biodistribution indicates that Fe-MOF-5-NH2-FA-5-FAM/5-FU can accumulate in the tumor.
|
31714562 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, Usp9x inactivation impaired intestinal regeneration and increased tumor burden in colitis-associated intestinal cancer. c-Myc heterozygosity abrogated increased progenitor proliferation and tumor burden in Usp9x-deficient mice, suggesting that Usp9x suppresses tumor formation by regulating Fbw7 protein stability and thereby reducing c-Myc.
|
29346117 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Usp9x inhibition by shRNA-knockdown or by G9 treatment reduced 3D colony formation in PANC1 and PDX cell lines, induced rapid apoptosis in MIAPACA2 cells, and associated with reduced Mcl-1 and ITCH protein levels.
|
29248719 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.
|
29449692 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, the molecular mechanism for USP9X regulation of tumor cell survival and tumorigenesis in NSCLC is less defined.
|
29721084 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The results of the present study indicate that USP9X may serve as a candidate tumor suppressor and prognostic biomarker in PDAC.
|
29844826 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Moreover, the in vivo biodistribution and antitumor assays indicate that UIO-66-NH2-FA-5-FAM/5-FU can accumulate in the tumor and display stronger antitumor efficiency due to the long-time drug release.
|
29560986 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Finally, the Usp9X pharmacological inhibitor WP1130 significantly reduced human MPNST growth and induced tumor cell death in an in vivo xenograft model.
|
30478285 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Moreover, expression of USP9X was positive correlated with MCL1 expression (P=0.006) and significant associated with lymph node metastasis (P=0.016), distant metastasis (P=0.001) and tumor staging (P=0.013) in gastric cancer.
|
28274596 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
FAM-CpG visualisation was used to demonstrate tumour targeting in vitro and in vivo.
|
27819142 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Many studies suggest that ubiquitin-specific peptidase 9, X-linked (<i>usp9x</i>) regulates multiple cellular behaviors, such as tumor growth, invasion, and resistance to chemotherapeutic agents.
|
28469783 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These data suggest that TRB3 functions as a sensor of tumor microenvironmental stress and together with USP9x induces the cell survival and tumor-promoting activities of Notch.
|
27593927 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
|
28720576 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Nevertheless, whether USP9X acts as a proto-oncogene or a tumor-suppressor gene in PDAC is controversial and the mechanism of metastasis remains unknown.
|
29130109 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
CP-d/n-ATF5-S1 promoted tumor cell apoptotic susceptibility in part by reducing expression of the deubiquitinase Usp9X and led to diminished levels of antiapoptotic Bcl-2 family members Mcl-1 and Bcl-2.
|
27126996 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Our findings demonstrate that USP9X is a novel regulator of pVHL stability, and USP9X may be a therapeutic target for treatment of VHL-related tumors.
|
27517496 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Using an integrative approach combining genomic and transcriptomic data, we molecularly characterized 30 pediatric T-ALLs and identified common recurrent T-ALL targets such as FBXW7, JAK1, JAK3, PHF6, KDM6A and NOTCH1 as well as novel candidate T-ALL driver mutations including the p.R35L missense mutation in splicesome factor U2AF1 found in 3 patients and loss of function mutations in the X-linked tumor suppressor genes MED12 (frameshit mutation p.V167fs, splice site mutation g.chrX:70339329T>C, missense mutation p.R1989H) and USP9X (nonsense mutation p.Q117*).
|
27602765 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
More importantly, in a peritoneal mouse tumor model, the systemic administration of the R11-SSPEI/FAM-miR-145 complex leads to the delivery of miR-145 into the tumors, dramatically inhibiting tumor growth and prolonged survival time.
|
26054847 |
2015 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
All tumors were evaluated for the presence of a YWHAE-FAM translocation; the translocation was demonstrated in the three Cyclin-D1 positive tumors.
|
25130488 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
It is primarily the recent revelations of USP9X's pivotal role in human cancers, both as oncogene or tumour suppressor, in developmental disorders including intellectual disability, epilepsy, autism and developmental delay that has led to a subsequent re-examination of its molecular and cellular functions.
|
25672900 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, other studies suggest that USP9X may function as a tumor-suppressor in a murine PDAC model when USP9X expression is depleted during early pancreatic development.
|
24841553 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Although previous work had attributed a pro-survival role to USP9X in human neoplasia, we found instead that loss of Usp9x enhances transformation and protects pancreatic cancer cells from anoikis.
|
22699621 |
2012 |